Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib plus Everolimus in c-kit positive acute myeloid leukemia
2007-000502-70Phase 2Terminated
- Sponsor
- Technical University of Munich
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib and everolimus in acute myeloid leukemia (AML), sponsored by Technical University of Munich. Primary endpoints: Hematological response rate and Duration of hematological response. Started Dec 2007; status: terminated.
02
Drugs
nilotinibeverolimus
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-000502-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000502-70.